Vaginal Challenge with an SIV-Based Dual Reporter System Reveals That Infection Can Occur throughout the Upper and Lower Female Reproductive Tract

English version České info

There is currently a great effort world-wide to develop interventions such as vaccines and microbicides to decrease, or hopefully block, HIV transmission. To model the infection of women, the field utilizes the rhesus macaque vaginal transmission model. Understanding the initial events leading to infection after viral challenge of the female reproductive tract (FRT) is crucial for the development of functional prevention strategies. To this end, we developed a novel method for detecting infection in the rhesus macaque FRT after vaginal inoculation. This method utilizes single round replication defective vector that expresses dual reporter proteins, Luciferase and mCherry. Monitoring Luciferase expression allows us to identify the sites of infection within the intact FRT, while fluorescent protein mCherry allows us to visualize the single infected cells. Our studies revealed that virus can access the entire upper and lower reproductive tract. Infection occurs primarily in vaginal and ectocervical tissue, but can spread as far as the ovary and local draining lymph nodes. All classically defined susceptible cell types can be infected with the broadly tropic HIV envelope utilized in this study. Prevention strategies aimed at protecting from HIV infection should consider the entire FRT architecture as potentially susceptible and design interventions accordingly.

Vyšlo v časopise: Vaginal Challenge with an SIV-Based Dual Reporter System Reveals That Infection Can Occur throughout the Upper and Lower Female Reproductive Tract. PLoS Pathog 10(10): e32767. doi:10.1371/journal.ppat.1004440
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004440

Souhrn

Zdroje

1. Joint United Nations Programme on HIV/AIDS. (2010) Global report: UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS. pp. v.

2. HaynesBF, McElrathMJ (2013) Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 8: 326–332.

3. ShattockRJ, MooreJP (2003) Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 1: 25–34.

4. HaaseAT (2011) Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 62: 127–139.

5. KeeleBF, EstesJD (2011) Barriers to mucosal transmission of immunodeficiency viruses. Blood 118: 839–846.

6. StoneM, KeeleBF, MaZM, BailesE, DutraJ, et al. (2010) A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 84: 7083–7095.

7. MillerCJ, LiQ, AbelK, KimEY, MaZM, et al. (2005) Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79: 9217–9227.

8. LiQ, EstesJD, SchlievertPM, DuanL, BrosnahanAJ, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458: 1034–1038.

9. GrantRM, LamaJR, AndersonPL, McMahanV, LiuAY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine 363: 2587–2599.

10. Abdool KarimQ, Abdool KarimSS, FrohlichJA, GroblerAC, BaxterC, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168–1174.

11. J Marrazzo GR, Nair G, et al.. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). Conference on Retroviruses and Opportunistic Infections Goergia World Congress Centre, Atlanta.

12. FriendDR, KiserPF (2013) Assessment of topical microbicides to prevent HIV-1 transmission: Concepts, testing, lessons learned. Antiviral Research 99: 391–400.

13. Van DammeL, CorneliA, AhmedK, AgotK, LombaardJ, et al. (2012) Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med

14. NegreD, MangeotPE, DuisitG, BlanchardS, VidalainPO, et al. (2000) Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 7: 1613–1623.

15. ShanerNC, CampbellRE, SteinbachPA, GiepmansBN, PalmerAE, et al. (2004) Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22: 1567–1572.

16. RabinovichBA, YeY, EttoT, ChenJQ, LevitskyHI, et al. (2008) Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A 105: 14342–14346.

17. KoyanagiY, MilesS, MitsuyasuRT, MerrillJE, VintersHV, et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236: 819–822.

18. CroninJ, ZhangXY, ReiserJ (2005) Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5: 387–398.

19. ZuffereyR, DonelloJE, TronoD, HopeTJ (1999) Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886–2892.

20. DonelloJE, LoebJE, HopeTJ (1998) Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 72: 5085–5092.

21. DurandS, CimarelliA (2011) The inside out of lentiviral vectors. Viruses 3: 132–159.

22. MarxPA, SpiraAI, GettieA, DaileyPJ, VeazeyRS, et al. (1996) Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 2: 1084–1089.

23. LeeB, SharronM, MontanerLJ, WeissmanD, DomsRW (1999) Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A 96: 5215–5220.

24. PooniaB, WalterL, DufourJ, HarrisonR, MarxPA, et al. (2006) Cyclic changes in the vaginal epithelium of normal rhesus macaques. J Endocrinol 190: 829–835.

25. MilushJM, KosubD, MarthasM, SchmidtK, ScottF, et al. (2004) Rapid dissemination of SIV following oral inoculation. AIDS 18: 2371–2380.

26. ZhangZ, SchulerT, ZupancicM, WietgrefeS, StaskusKA, et al. (1999) Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286: 1353–1357.

27. MillerCJ, ShattockRJ (2003) Target cells in vaginal HIV transmission. Microbes Infect 5: 59–67.

28. SpiraAI, MarxPA, PattersonBK, MahoneyJ, KoupRA, et al. (1996) Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183: 215–225.

29. HladikF, SakchalathornP, BallweberL, LentzG, FialkowM, et al. (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26: 257–270.

30. PandreaI, ParrishNF, RaehtzK, GaufinT, BarbianHJ, et al. (2012) Mucosal simian immunodeficiency virus transmission in African green monkeys: susceptibility to infection is proportional to target cell availability at mucosal sites. J Virol 86: 4158–4168.

31. WiraCR, FaheyJV (2008) A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 22: 1909–1917.

32. CramerDW, WelchWR, BerkowitzRS, GodleskiJJ (2007) Presence of talc in pelvic lymph nodes of a woman with ovarian cancer and long-term genital exposure to cosmetic talc. Obstetrics and gynecology 110: 498–501.

33. RosenblattKA, WeissNS, Cushing-HaugenKL, WicklundKG, RossingMA (2011) Genital powder exposure and the risk of epithelial ovarian cancer. Cancer Causes Control 22: 737–742.

34. CookLS, KambML, WeissNS (1997) Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 145: 459–465.

35. BlumenkrantzMJ, GallagherN, BashoreRA, TenckhoffH (1981) Retrograde menstruation in women undergoing chronic peritoneal dialysis. Obstetrics and gynecology 57: 667–670.

36. HalmeJ, HammondMG, HulkaJF, RajSG, TalbertLM (1984) Retrograde menstruation in healthy women and in patients with endometriosis. Obstetrics and gynecology 64: 151–154.

37. MasurierC, SalomonB, GuettariN, PiocheC, LachapelleF, et al. (1998) Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. J Virol 72: 7822–7829.

38. GhanemKG, ShahN, KleinRS, MayerKH, SobelJD, et al. (2005) Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis 191: 358–366.

39. RotchfordK, StrumAW, WilkinsonD (2000) Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis 27: 243–248.

40. VishwanathanSA, GuenthnerPC, LinCY, DobardC, SharmaS, et al. (2011) High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 57: 261–264.

41. KershEN, HenningT, VishwanathanSA, MorrisM, ButlerK, et al. (2014) SHIV susceptibility changes during the menstrual cycle of pigtail macaques. J Med Primatol [epub ahead of print]..

42. AkiyamaM, OkabeH, TakakuraK, FujiyamaY, NodaY (1999) Expression of macrophage inflammatory protein-1alpha (MIP-1alpha) in human endometrium throughout the menstrual cycle. Br J Obstet Gynaecol 106: 725–730.

43. KallikourdisM, AndersenKG, WelchKA, BetzAG (2007) Alloantigen-enhanced accumulation of CCR5+ ‘effector’ regulatory T cells in the gravid uterus. Proc Natl Acad Sci U S A 104: 594–599.

44. PadianNS, van der StratenA, RamjeeG, ChipatoT, de BruynG, et al. (2007) Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 370: 251–261.

45. WeiX, DeckerJM, LiuH, ZhangZ, AraniRB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905.